Showing 696 results
-
Media Release /Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolio C3…
-
Media Release /NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across…
-
Media Release /Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell…
-
Media Release /Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo…
-
Media Release /PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-…
-
Media Release /After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor…
-
Media Release /In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1…
-
Media Release /Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-controlled disease observed as fast as two…
-
Media Release /Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products;…
-
Media Release /ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after…
